A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

365

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

March 31, 2028

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

A166

intravenous(IV) infusion (Q3W)

DRUG

T-DM1

intravenous(IV) infusion (Q3W)

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY